Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
EMD Serono
Sanofi
University Hospital, Limoges
Abramson Cancer Center at Penn Medicine
Wake Forest University Health Sciences
Novartis
Novartis
Samsung Bioepis Co., Ltd.
Menoufia University
Bristol-Myers Squibb
AstraZeneca
AstraZeneca
Swiss Cancer Institute
Canadian Cancer Trials Group
Bristol-Myers Squibb
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Georgetown University
On Target Laboratories, LLC
Intergroupe Francophone de Cancerologie Thoracique
Intergroupe Francophone de Cancerologie Thoracique
Innovent Biologics (Suzhou) Co. Ltd.
Bristol-Myers Squibb
Ionis Pharmaceuticals, Inc.
HTA Co., Ltd.
Alliance for Clinical Trials in Oncology
St. Joseph's Healthcare Hamilton
Radiation Therapy Oncology Group
Sumitomo Pharma Co., Ltd.
The Netherlands Cancer Institute
AstraZeneca
University of Wisconsin, Madison
Wake Forest University Health Sciences
Wake Forest University Health Sciences
Takeda
UNICANCER
Genentech, Inc.
Merck Sharp & Dohme LLC
Ciusss de L'Est de l'Île de Montréal
Celgene
Canadian Cancer Trials Group
Canadian Cancer Trials Group
Canadian Cancer Trials Group
Shanghai Pulmonary Hospital, Shanghai, China
Celgene
Eli Lilly and Company
Shanghai University of Traditional Chinese Medicine
Amgen
SWOG Cancer Research Network